Lexaria Bioscience Corp.
LEXX
$1.35
-$0.34-20.12%
NASDAQ
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 29.95% | 77.65% | 105.35% | 34.05% | 23.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.95% | 77.65% | 105.35% | 34.05% | 23.16% |
| Cost of Revenue | -84.57% | -86.83% | -84.76% | -93.40% | -77.74% |
| Gross Profit | 35.12% | 90.59% | 136.00% | 73.66% | 54.88% |
| SG&A Expenses | 76.95% | 47.20% | 28.38% | 6.59% | -30.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 75.37% | 25.90% | -7.43% | -23.27% | -13.73% |
| Operating Income | -78.89% | -23.43% | 11.39% | 26.12% | 15.69% |
| Income Before Tax | -71.74% | -19.61% | 13.47% | 30.18% | 21.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -71.74% | -19.61% | 13.47% | 30.18% | 21.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -63.84% | -73.75% | -72.12% | -74.67% | -71.31% |
| Net Income | -72.50% | -20.23% | 13.05% | 29.64% | 21.22% |
| EBIT | -78.89% | -23.43% | 11.39% | 26.12% | 15.69% |
| EBITDA | -82.53% | -25.25% | 10.55% | 27.06% | 16.64% |
| EPS Basic | 17.83% | 43.62% | 55.69% | 58.15% | 38.66% |
| Normalized Basic EPS | 14.10% | 41.62% | 54.67% | 55.79% | 33.07% |
| EPS Diluted | 17.83% | 43.62% | 55.69% | 58.15% | 38.66% |
| Normalized Diluted EPS | 14.10% | 41.62% | 54.67% | 55.79% | 33.07% |
| Average Basic Shares Outstanding | 85.50% | 92.88% | 86.70% | 71.97% | 44.36% |
| Average Diluted Shares Outstanding | 85.50% | 92.88% | 86.70% | 71.97% | 44.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |